IGF-1 LR3

IGF-1 LR3 is IGF-1 with two deliberate changes: arginine in place of glutamate at position 3, and a 13-residue hydrophobic extension added to the N terminus [1]. The point of both is the same. In the body, almost all IGF-1 is bound up by the IGF binding proteins, and only a small free fraction reaches the receptor. Take away the binding-protein affinity and you get a molecule that is, in cell culture, far more potent per microgram than IGF-1 [2]. That is what it was made for: it is a standard supplement for growing cells in a dish, and a tool for animal physiology.

What the animal work actually shows. The results are not a muscle-growth story. In finisher pigs, a four-day infusion at 180 µg/kg/day decreased average daily gain and food intake, and suppressed plasma IGFBP-3, IGF-I and insulin; mean growth hormone fell 23% and the area under the GH peaks fell 60%. The authors concluded the suppression of the pig's own somatotropic axis probably explains why the analogue inhibits growth in that species [3]. In guinea pigs, seven days of infusion raised the fractional weights of adrenals, gut, kidneys and spleen but did not stimulate overall growth, and lowered circulating IGF-I, IGF-II and binding proteins [2]. Where it does something clearly useful it is in the gut: in rats it enlarged the intestinal mucosa enough to raise absorption of a glucose analogue by up to 69% per centimetre of jejunum [5], and pepsin-resistant muteins were designed with oral treatment of gastric damage in mind [6].

Human evidence. There is none. No trial, no pharmacokinetic study, no case series. A 2026 review of the peptides people self-administer to work on the GH–IGF-1 axis places it among the compounds whose use runs well ahead of any clinical evidence [7]. What exists instead is antidoping literature: the analogue is prohibited in sport, methods to detect it in serum have been validated [8], and the wider problem of IGF-I misuse and its detection has its own review literature [9][10][11].

What is actually in the vials. In one documented case a black-market injection vial was found to contain Long-R3-IGF-I carrying a C-terminal His6 tag — the affinity handle used to purify proteins in a laboratory, normally removed before anything is used in an animal. The authors' conclusion was blunt: the product was probably a by-product of biochemical research rather than something made to be injected, and the effects of His-tagged Long-R3-IGF-I in humans have never been described [4]. The antidoping validation study separately found "abundant" oxidised, lower-quality peptide forms in black-market material [8].

IGF-1 signals through the IGF-1 receptor, a tyrosine kinase that drives the PI3K/Akt and MAPK pathways behind cell growth, protein synthesis and survival [12]. Its availability is controlled by six binding proteins, principally IGFBP-3, which hold the great majority of circulating IGF-1 in ternary complexes and release it slowly.

LR3 is an attempt to bypass that control. Arg3 removes a contact the binding proteins need, and the N-terminal extension adds bulk and changes the folding pathway of the molecule [1]. In practice the escape is partial rather than total: in cultured cells, IGFBP-3 inhibited receptor phosphorylation induced by Long(R3)IGF-I over the same concentration range as it inhibited IGF-I, by sequestering the analogue rather than by touching the receptor [13]. Freer, then, but not free.

There is a second-order effect that the design does not escape, and which the pig data make plain. IGF-1 feeds back on the pituitary to suppress growth hormone. An analogue with a long free half-life in the receptor-accessible compartment is an unusually effective suppressor, so the animal's own GH, IGF-1 and IGFBP-3 all fall [2][3]. Whether the net effect on an animal is growth or shrinkage then depends on whether the exogenous signal outweighs the endogenous axis it switches off — and in pigs it did not.

The molecule is a 83-residue protein: the 70 residues of human IGF-1 with Arg at position 3, preceded by a 13-residue extension derived from methionyl porcine growth hormone, with IGF-1's three disulfide bridges [1]. It is made recombinantly, usually in E. coli, and refolding it correctly is non-trivial — the disulfide-intermediate work exists precisely because IGF-1 and LR3 misfold readily [1].

Research-grade protein is often produced with a polyhistidine tag for purification. Tags on the N terminus are enzymatically removed; a C-terminal tag on the material found in a black-market vial was not [4]. Oral use is defeated by pepsin, which cleaves the extension within minutes; the Phe16Ala mutein was built to resist this and retained full growth-promoting activity, but it is a laboratory construct, not a product [6].

There is no human safety data for IGF-1 LR3 — no trial, no pharmacovigilance, nothing. What can be said comes from two indirect sources.

What IGF-1 itself does in people. Recombinant IGF-1 (mecasermin) is a licensed drug for severe primary IGF-1 deficiency, and its dose-limiting problem is hypoglycaemia [15]. In the European Increlex registry, 80 of 306 treated children had at least one hypoglycaemia event, at a rate of 0.11 events per patient per treatment year, with prior hypoglycaemia and Laron syndrome the strongest predictors [16]. Other adverse effects reported with rhIGF-1 in registries and case series include tonsillar hypertrophy and intracranial hypertension — one child in a pharmacokinetic study stopped treatment because of pseudotumor cerebri [17][18]. An analogue designed to evade the binding proteins delivers more free IGF-1 activity per microgram, so there is no reason to expect a wider hypoglycaemic margin and some reason to expect a narrower one.

The cancer question. Higher circulating IGF-1 is associated with modestly higher risk of prostate and premenopausal breast cancer in pooled epidemiology [19], and a meta-analysis of individual participant data from 19 studies found an odds ratio of 1.29 for prostate cancer comparing the highest with the lowest fifth of IGF-I [20]. These are observational associations in people with naturally varying IGF-1, not a measured consequence of injecting an analogue, and the effect sizes are small. They are the reason the question is asked at all, and nobody has the data to answer it for LR3. The relationship with all-cause mortality is U-shaped rather than linear: in a meta-analysis of 12 cohorts and 14,906 people, both the 10th and the 90th percentile of IGF-I carried higher mortality than the median, with hazard ratios of 1.56 and 1.29 respectively [21]. Low IGF-1 is not safe either, which is the point of treating people who genuinely lack it — in the Increlex registry, children reaching near-adult height on rhIGF-1 gained a mean 0.9 height standard deviation scores, and 1.4 in those treated before puberty [22]. None of that is an argument for raising IGF-1 activity in someone whose axis is intact.

Product quality. This is a concrete and documented risk rather than a theoretical one: a vial sold as Long-R3-IGF-I contained His-tagged reagent whose effects in humans are unknown [4], and black-market samples analysed for antidoping purposes contained large amounts of oxidised peptide [8].

No human interaction data exist. In pigs, co-administering porcine growth hormone with LR3 did not rescue the lost weight gain, and the suppression of insulin, IGFBP-3 and IGF-I persisted [3] — an interaction worth knowing for anyone assuming that stacking a secretagogue on top restores the axis.

Mechanistically, anything that raises IGF-1 activity adds to the hypoglycaemic risk seen with recombinant IGF-1 [16], which makes insulin and the GH secretagogues the obvious pairings to treat with caution.